curasan AG
curasan launches CERASORB(R) Ortho Foam in US Orthopedics Market
DGAP-News: curasan AG / Key word(s): Product Launch – Successful first implantation case with advanced bone graft material – Entry into biggest orthopedics market worldwide
Kleinostheim, Germany/Research Triangle Park, USA, 11 May 2017 – curasan Inc., the US-subsidiary of curasan AG (ISIN DE0005494538), a leading specialist for medical products in the field of orthobiologics, today announced the first implantation of their CERASORB(R) Ortho Foam advanced bone graft product signaling curasan’s entrance in the US orthopedics market. The United States orthopedics market, specifically for bone grafting products, is the largest market globally with annual market potential of over $800 million USD. CERASORB(R) Ortho Foam was used in a challenging knee arthrodesis case performed by Dr. Divakar Krishnareddy at Los Angeles Community Hospital in Los Angeles, California. Dr. Krishnareddy commented on the product: “It’s exciting to see a product that has both excellent handling and strong clinical evidence become available in the USA. CERASORB(R) Ortho Foam’s handling is very easy to adapt to underlying anatomy while preventing leaving large gaps allowing graft placement where you need it.” “curasan has a strong 20 plus year history of delivering novel and highly effective materials for the bone regeneration market. With numerous patents, peer-reviewed clinical studies, and robust on-going research and development and clinical programs, we provide cost-effective and clinically proven orthobiologic solutions that integrate seamlessly in the operating room,” said M. Shane Ray, President of curasan, Inc. “We are excited at entering the orthopedic market here in the United States and look forward to working with our sales partners to provide advanced biomaterials to our surgeon customers throughout the USA”. About curasan AG: Contact: Ingo Middelmenne Head of Investor Relations Tel. +49 6027 40900-45 Fax +49 6027 40900-39 ingo.middelmenne@curasan.de Andrea Weidner Head of Corporate Communications Tel. +49 6027 40900-51 Fax +49 6027 40900-39 andrea.weidner@curasan.de www.curasan.de
11.05.2017 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. |
Language: | English |
Company: | curasan AG |
Lindigstraße 4 | |
63801 Kleinostheim | |
Germany | |
Phone: | 06027/40 900 0 |
Fax: | 06027/40 900 29 |
E-mail: | info@curasan.de |
Internet: | www.curasan.de |
ISIN: | DE0005494538 |
WKN: | 549453 |
Listed: | Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
End of News | DGAP News Service |